nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0794	0.201	CbGbCtD
Trametinib—CYP2C8—Dexamethasone—ankylosing spondylitis	0.0741	0.188	CbGbCtD
Trametinib—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0602	0.153	CbGbCtD
Trametinib—CYP3A4—Betamethasone—ankylosing spondylitis	0.0516	0.131	CbGbCtD
Trametinib—CYP3A4—Prednisolone—ankylosing spondylitis	0.0509	0.129	CbGbCtD
Trametinib—CYP3A4—Prednisone—ankylosing spondylitis	0.0481	0.122	CbGbCtD
Trametinib—CYP3A4—Dexamethasone—ankylosing spondylitis	0.03	0.0762	CbGbCtD
Trametinib—MAP2K2—Uptake and function of anthrax toxins—ANTXR2—ankylosing spondylitis	0.0299	0.0975	CbGpPWpGaD
Trametinib—MAP2K1—Uptake and function of anthrax toxins—ANTXR2—ankylosing spondylitis	0.028	0.0912	CbGpPWpGaD
Trametinib—MAP2K2—Cellular roles of Anthrax toxin—ANTXR2—ankylosing spondylitis	0.0196	0.064	CbGpPWpGaD
Trametinib—MAP2K2—Uptake and actions of bacterial toxins—ANTXR2—ankylosing spondylitis	0.0189	0.0618	CbGpPWpGaD
Trametinib—MAP2K1—Cellular roles of Anthrax toxin—ANTXR2—ankylosing spondylitis	0.0184	0.0599	CbGpPWpGaD
Trametinib—MAP2K1—Uptake and actions of bacterial toxins—ANTXR2—ankylosing spondylitis	0.0177	0.0578	CbGpPWpGaD
Trametinib—MAP2K1—Senescence and Autophagy in Cancer—CREG1—ankylosing spondylitis	0.00916	0.0299	CbGpPWpGaD
Trametinib—MAP2K1—Interleukin-1 signaling—IL1R2—ankylosing spondylitis	0.0091	0.0297	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by Interleukins—IL1R2—ankylosing spondylitis	0.00439	0.0143	CbGpPWpGaD
Trametinib—MAP2K1—Interleukin-1 signaling—IL1RN—ankylosing spondylitis	0.0043	0.014	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by Interleukins—IL1R2—ankylosing spondylitis	0.00411	0.0134	CbGpPWpGaD
Trametinib—MAP2K1—Interleukin-1 signaling—IL1A—ankylosing spondylitis	0.0031	0.0101	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.00309	0.0101	CbGpPWpGaD
Trametinib—MAP2K2—Structural Pathway of Interleukin 1 (IL-1)—IL1A—ankylosing spondylitis	0.00291	0.00949	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.00289	0.00941	CbGpPWpGaD
Trametinib—MAP2K2—Leptin signaling pathway—IL1RN—ankylosing spondylitis	0.00278	0.00907	CbGpPWpGaD
Trametinib—MAP2K1—Structural Pathway of Interleukin 1 (IL-1)—IL1A—ankylosing spondylitis	0.00272	0.00888	CbGpPWpGaD
Trametinib—MAP2K2—IL-6 signaling pathway—CRP—ankylosing spondylitis	0.00261	0.00852	CbGpPWpGaD
Trametinib—MAP2K1—Leptin signaling pathway—IL1RN—ankylosing spondylitis	0.0026	0.00849	CbGpPWpGaD
Trametinib—MAP2K2—IL-1 signaling pathway—IL1A—ankylosing spondylitis	0.00257	0.00837	CbGpPWpGaD
Trametinib—MAP2K2—TCR Signaling Pathway—IL17A—ankylosing spondylitis	0.00253	0.00826	CbGpPWpGaD
Trametinib—MAP2K1—BCR signaling pathway—CD79A—ankylosing spondylitis	0.0025	0.00816	CbGpPWpGaD
Trametinib—MAP2K1—IL-6 signaling pathway—CRP—ankylosing spondylitis	0.00244	0.00797	CbGpPWpGaD
Trametinib—MAP2K1—IL-1 signaling pathway—IL1A—ankylosing spondylitis	0.0024	0.00783	CbGpPWpGaD
Trametinib—MAP2K2—Oncostatin M Signaling Pathway—MMP3—ankylosing spondylitis	0.00237	0.00774	CbGpPWpGaD
Trametinib—MAP2K1—TCR Signaling Pathway—IL17A—ankylosing spondylitis	0.00237	0.00772	CbGpPWpGaD
Trametinib—MAP2K1—Oncostatin M Signaling Pathway—MMP3—ankylosing spondylitis	0.00222	0.00725	CbGpPWpGaD
Trametinib—MAP2K2—Toll-like Receptor Signaling Pathway—IL12B—ankylosing spondylitis	0.00213	0.00694	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by Interleukins—IL1RN—ankylosing spondylitis	0.00208	0.00678	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—IL1R2—ankylosing spondylitis	0.00205	0.00669	CbGpPWpGaD
Trametinib—MAP2K2—Cellular roles of Anthrax toxin—TNF—ankylosing spondylitis	0.00202	0.00659	CbGpPWpGaD
Trametinib—MAP2K1—Toll-like Receptor Signaling Pathway—IL12B—ankylosing spondylitis	0.00199	0.0065	CbGpPWpGaD
Trametinib—MAP2K2—B Cell Receptor Signaling Pathway—CD79A—ankylosing spondylitis	0.00199	0.00648	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by Interleukins—IL1RN—ankylosing spondylitis	0.00194	0.00634	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.00194	0.00634	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—IL1R2—ankylosing spondylitis	0.00192	0.00626	CbGpPWpGaD
Trametinib—MAP2K1—Cellular roles of Anthrax toxin—TNF—ankylosing spondylitis	0.00189	0.00617	CbGpPWpGaD
Trametinib—MAP2K1—B Cell Receptor Signaling Pathway—CD79A—ankylosing spondylitis	0.00186	0.00607	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.00182	0.00593	CbGpPWpGaD
Trametinib—MAP2K2—TCR Signaling Pathway—IL1A—ankylosing spondylitis	0.00173	0.00564	CbGpPWpGaD
Trametinib—MAP2K2—Regulation of toll-like receptor signaling pathway—IL12B—ankylosing spondylitis	0.00166	0.00542	CbGpPWpGaD
Trametinib—MAP2K1—TCR Signaling Pathway—IL1A—ankylosing spondylitis	0.00162	0.00528	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—HLA-C—ankylosing spondylitis	0.00161	0.00525	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of toll-like receptor signaling pathway—IL12B—ankylosing spondylitis	0.00156	0.00507	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—HLA-C—ankylosing spondylitis	0.00151	0.00492	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by Interleukins—IL1A—ankylosing spondylitis	0.0015	0.00488	CbGpPWpGaD
Trametinib—MAP2K1—Senescence and Autophagy in Cancer—IL1A—ankylosing spondylitis	0.00143	0.00467	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by Interleukins—IL1A—ankylosing spondylitis	0.0014	0.00456	CbGpPWpGaD
Trametinib—MAP2K2—MyD88:Mal cascade initiated on plasma membrane—TLR4—ankylosing spondylitis	0.00134	0.00437	CbGpPWpGaD
Trametinib—MAP2K2—Amyotrophic lateral sclerosis (ALS)—TNF—ankylosing spondylitis	0.00131	0.00426	CbGpPWpGaD
Trametinib—MAP2K2—MyD88-independent cascade—TLR4—ankylosing spondylitis	0.00129	0.00419	CbGpPWpGaD
Trametinib—MAP2K1—Corticotropin-releasing hormone—TLR4—ankylosing spondylitis	0.00128	0.00416	CbGpPWpGaD
Trametinib—MAP2K2—Toll-like Receptor Signaling Pathway—TLR4—ankylosing spondylitis	0.00125	0.00409	CbGpPWpGaD
Trametinib—MAP2K1—MyD88:Mal cascade initiated on plasma membrane—TLR4—ankylosing spondylitis	0.00125	0.00409	CbGpPWpGaD
Trametinib—MAP2K1—MyD88-independent cascade—TLR4—ankylosing spondylitis	0.0012	0.00392	CbGpPWpGaD
Trametinib—MAP2K1—Toll-like Receptor Signaling Pathway—TLR4—ankylosing spondylitis	0.00117	0.00383	CbGpPWpGaD
Trametinib—MAP2K2—Activated TLR4 signalling—TLR4—ankylosing spondylitis	0.00116	0.00377	CbGpPWpGaD
Trametinib—Melaena—Methotrexate—ankylosing spondylitis	0.00112	0.00376	CcSEcCtD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—HLA-C—ankylosing spondylitis	0.00112	0.00364	CbGpPWpGaD
Trametinib—Alanine aminotransferase increased—Methylprednisolone—ankylosing spondylitis	0.00111	0.00372	CcSEcCtD
Trametinib—MAP2K2—Immune System—KIR3DL1—ankylosing spondylitis	0.00111	0.0036	CbGpPWpGaD
Trametinib—Cardiac failure congestive—Prednisone—ankylosing spondylitis	0.0011	0.00368	CcSEcCtD
Trametinib—MAP2K2—Toll Like Receptor 4 (TLR4) Cascade—TLR4—ankylosing spondylitis	0.00109	0.00355	CbGpPWpGaD
Trametinib—MAP2K2—Ceramide signaling pathway—TNF—ankylosing spondylitis	0.00108	0.00353	CbGpPWpGaD
Trametinib—MAP2K1—Activated TLR4 signalling—TLR4—ankylosing spondylitis	0.00108	0.00353	CbGpPWpGaD
Trametinib—Pancreatitis—Triamcinolone—ankylosing spondylitis	0.00107	0.00358	CcSEcCtD
Trametinib—Pancreatitis—Methylprednisolone—ankylosing spondylitis	0.00107	0.00358	CcSEcCtD
Trametinib—Dry skin—Betamethasone—ankylosing spondylitis	0.00105	0.00352	CcSEcCtD
Trametinib—Dry skin—Dexamethasone—ankylosing spondylitis	0.00105	0.00352	CcSEcCtD
Trametinib—MAP2K2—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	0.00105	0.00343	CbGpPWpGaD
Trametinib—MAP2K1—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	0.00105	0.00342	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—HLA-C—ankylosing spondylitis	0.00104	0.00341	CbGpPWpGaD
Trametinib—Hypokalaemia—Dexamethasone—ankylosing spondylitis	0.00104	0.00349	CcSEcCtD
Trametinib—Hypokalaemia—Betamethasone—ankylosing spondylitis	0.00104	0.00349	CcSEcCtD
Trametinib—Neoplasm—Methotrexate—ankylosing spondylitis	0.00104	0.00348	CcSEcCtD
Trametinib—Mouth ulceration—Methotrexate—ankylosing spondylitis	0.00104	0.00348	CcSEcCtD
Trametinib—MAP2K1—Immune System—KIR3DL1—ankylosing spondylitis	0.00103	0.00337	CbGpPWpGaD
Trametinib—MAP2K1—Toll Like Receptor 4 (TLR4) Cascade—TLR4—ankylosing spondylitis	0.00102	0.00332	CbGpPWpGaD
Trametinib—MAP2K1—Ceramide signaling pathway—TNF—ankylosing spondylitis	0.00101	0.0033	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CARD9—ankylosing spondylitis	0.000997	0.00325	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	0.000983	0.00321	CbGpPWpGaD
Trametinib—MAP2K2—Regulation of toll-like receptor signaling pathway—TLR4—ankylosing spondylitis	0.00098	0.00319	CbGpPWpGaD
Trametinib—Infestation—Methylprednisolone—ankylosing spondylitis	0.000972	0.00325	CcSEcCtD
Trametinib—Infestation NOS—Methylprednisolone—ankylosing spondylitis	0.000972	0.00325	CcSEcCtD
Trametinib—MAP2K2—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.000971	0.00317	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.00097	0.00316	CbGpPWpGaD
Trametinib—MAP2K2—Toll-Like Receptors Cascades—TLR4—ankylosing spondylitis	0.000969	0.00316	CbGpPWpGaD
Trametinib—Bradycardia—Prednisolone—ankylosing spondylitis	0.000968	0.00324	CcSEcCtD
Trametinib—Haemoglobin—Prednisolone—ankylosing spondylitis	0.000956	0.0032	CcSEcCtD
Trametinib—MAP2K2—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000953	0.00311	CbGpPWpGaD
Trametinib—Haemorrhage—Prednisolone—ankylosing spondylitis	0.000951	0.00318	CcSEcCtD
Trametinib—MAP2K1—Innate Immune System—CARD9—ankylosing spondylitis	0.000933	0.00304	CbGpPWpGaD
Trametinib—Epistaxis—Triamcinolone—ankylosing spondylitis	0.000919	0.00307	CcSEcCtD
Trametinib—MAP2K1—Regulation of toll-like receptor signaling pathway—TLR4—ankylosing spondylitis	0.000917	0.00299	CbGpPWpGaD
Trametinib—Dry skin—Prednisone—ankylosing spondylitis	0.000916	0.00306	CcSEcCtD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000912	0.00297	CbGpPWpGaD
Trametinib—Hypokalaemia—Prednisone—ankylosing spondylitis	0.000909	0.00304	CcSEcCtD
Trametinib—MAP2K1—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.000909	0.00296	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.000907	0.00296	CbGpPWpGaD
Trametinib—MAP2K1—Toll-Like Receptors Cascades—TLR4—ankylosing spondylitis	0.000906	0.00296	CbGpPWpGaD
Trametinib—Renal failure acute—Methotrexate—ankylosing spondylitis	0.000904	0.00302	CcSEcCtD
Trametinib—Hyperglycaemia—Betamethasone—ankylosing spondylitis	0.000894	0.00299	CcSEcCtD
Trametinib—Hyperglycaemia—Dexamethasone—ankylosing spondylitis	0.000894	0.00299	CcSEcCtD
Trametinib—MAP2K1—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000891	0.00291	CbGpPWpGaD
Trametinib—Bradycardia—Triamcinolone—ankylosing spondylitis	0.00089	0.00298	CcSEcCtD
Trametinib—Bradycardia—Methylprednisolone—ankylosing spondylitis	0.000889	0.00297	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Prednisone—ankylosing spondylitis	0.000881	0.00295	CcSEcCtD
Trametinib—Haemoglobin—Triamcinolone—ankylosing spondylitis	0.000879	0.00294	CcSEcCtD
Trametinib—Haemoglobin—Methylprednisolone—ankylosing spondylitis	0.000877	0.00293	CcSEcCtD
Trametinib—Haemorrhage—Triamcinolone—ankylosing spondylitis	0.000875	0.00293	CcSEcCtD
Trametinib—Haemorrhage—Methylprednisolone—ankylosing spondylitis	0.000873	0.00292	CcSEcCtD
Trametinib—Connective tissue disorder—Methylprednisolone—ankylosing spondylitis	0.000858	0.00287	CcSEcCtD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000853	0.00278	CbGpPWpGaD
Trametinib—Arrhythmia—Prednisolone—ankylosing spondylitis	0.00085	0.00284	CcSEcCtD
Trametinib—Pancreatitis—Prednisone—ankylosing spondylitis	0.000847	0.00283	CcSEcCtD
Trametinib—MAP2K2—Downstream signaling in naïve CD8+ T cells—TNF—ankylosing spondylitis	0.000839	0.00274	CbGpPWpGaD
Trametinib—Erythema—Prednisolone—ankylosing spondylitis	0.000828	0.00277	CcSEcCtD
Trametinib—Eye disorder—Methylprednisolone—ankylosing spondylitis	0.000816	0.00273	CcSEcCtD
Trametinib—Cardiac disorder—Methylprednisolone—ankylosing spondylitis	0.00081	0.00271	CcSEcCtD
Trametinib—Bradycardia—Betamethasone—ankylosing spondylitis	0.000808	0.0027	CcSEcCtD
Trametinib—Bradycardia—Dexamethasone—ankylosing spondylitis	0.000808	0.0027	CcSEcCtD
Trametinib—Neutropenia—Prednisone—ankylosing spondylitis	0.000807	0.0027	CcSEcCtD
Trametinib—Haemoglobin—Dexamethasone—ankylosing spondylitis	0.000798	0.00267	CcSEcCtD
Trametinib—Haemoglobin—Betamethasone—ankylosing spondylitis	0.000798	0.00267	CcSEcCtD
Trametinib—Haemorrhage—Dexamethasone—ankylosing spondylitis	0.000794	0.00265	CcSEcCtD
Trametinib—Haemorrhage—Betamethasone—ankylosing spondylitis	0.000794	0.00265	CcSEcCtD
Trametinib—Angiopathy—Methylprednisolone—ankylosing spondylitis	0.000792	0.00265	CcSEcCtD
Trametinib—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.000787	0.00263	CcSEcCtD
Trametinib—MAP2K1—Downstream signaling in naïve CD8+ T cells—TNF—ankylosing spondylitis	0.000785	0.00256	CbGpPWpGaD
Trametinib—Arrhythmia—Triamcinolone—ankylosing spondylitis	0.000781	0.00261	CcSEcCtD
Trametinib—Vision blurred—Prednisolone—ankylosing spondylitis	0.00078	0.00261	CcSEcCtD
Trametinib—Arrhythmia—Methylprednisolone—ankylosing spondylitis	0.00078	0.00261	CcSEcCtD
Trametinib—Hyperglycaemia—Prednisone—ankylosing spondylitis	0.000779	0.00261	CcSEcCtD
Trametinib—MAP2K2—Disease—ANTXR2—ankylosing spondylitis	0.000773	0.00252	CbGpPWpGaD
Trametinib—Mental disorder—Methylprednisolone—ankylosing spondylitis	0.000765	0.00256	CcSEcCtD
Trametinib—Erythema—Triamcinolone—ankylosing spondylitis	0.000761	0.00255	CcSEcCtD
Trametinib—Erythema—Methylprednisolone—ankylosing spondylitis	0.00076	0.00254	CcSEcCtD
Trametinib—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.00076	0.00254	CcSEcCtD
Trametinib—Dysgeusia—Triamcinolone—ankylosing spondylitis	0.000746	0.00249	CcSEcCtD
Trametinib—Eye disorder—Dexamethasone—ankylosing spondylitis	0.000742	0.00248	CcSEcCtD
Trametinib—Eye disorder—Betamethasone—ankylosing spondylitis	0.000742	0.00248	CcSEcCtD
Trametinib—Back pain—Triamcinolone—ankylosing spondylitis	0.000737	0.00246	CcSEcCtD
Trametinib—MAP2K1—Disease—ANTXR2—ankylosing spondylitis	0.000724	0.00236	CbGpPWpGaD
Trametinib—Angiopathy—Betamethasone—ankylosing spondylitis	0.00072	0.00241	CcSEcCtD
Trametinib—Angiopathy—Dexamethasone—ankylosing spondylitis	0.00072	0.00241	CcSEcCtD
Trametinib—Hypertension—Prednisolone—ankylosing spondylitis	0.000715	0.00239	CcSEcCtD
Trametinib—Arrhythmia—Dexamethasone—ankylosing spondylitis	0.000709	0.00237	CcSEcCtD
Trametinib—Arrhythmia—Betamethasone—ankylosing spondylitis	0.000709	0.00237	CcSEcCtD
Trametinib—Pancreatitis—Methotrexate—ankylosing spondylitis	0.000708	0.00237	CcSEcCtD
Trametinib—Bradycardia—Prednisone—ankylosing spondylitis	0.000704	0.00235	CcSEcCtD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000698	0.00228	CbGpPWpGaD
Trametinib—Haemoglobin—Prednisone—ankylosing spondylitis	0.000695	0.00232	CcSEcCtD
Trametinib—MAP2K2—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	0.000692	0.00226	CbGpPWpGaD
Trametinib—Abdominal discomfort—Methotrexate—ankylosing spondylitis	0.000692	0.00231	CcSEcCtD
Trametinib—Haemorrhage—Prednisone—ankylosing spondylitis	0.000691	0.00231	CcSEcCtD
Trametinib—Erythema—Dexamethasone—ankylosing spondylitis	0.000691	0.00231	CcSEcCtD
Trametinib—Erythema—Betamethasone—ankylosing spondylitis	0.000691	0.00231	CcSEcCtD
Trametinib—Connective tissue disorder—Prednisone—ankylosing spondylitis	0.000679	0.00227	CcSEcCtD
Trametinib—Oedema—Prednisolone—ankylosing spondylitis	0.000676	0.00226	CcSEcCtD
Trametinib—Neutropenia—Methotrexate—ankylosing spondylitis	0.000675	0.00226	CcSEcCtD
Trametinib—MAP2K2—Immune System—IL1R2—ankylosing spondylitis	0.00067	0.00218	CbGpPWpGaD
Trametinib—Cough—Triamcinolone—ankylosing spondylitis	0.000664	0.00222	CcSEcCtD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.00066	0.00215	CbGpPWpGaD
Trametinib—Hypertension—Triamcinolone—ankylosing spondylitis	0.000657	0.0022	CcSEcCtD
Trametinib—Hypertension—Methylprednisolone—ankylosing spondylitis	0.000656	0.00219	CcSEcCtD
Trametinib—Hyperhidrosis—Prednisolone—ankylosing spondylitis	0.000653	0.00218	CcSEcCtD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000653	0.00213	CbGpPWpGaD
Trametinib—Myalgia—Triamcinolone—ankylosing spondylitis	0.000648	0.00217	CcSEcCtD
Trametinib—MAP2K1—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	0.000647	0.00211	CbGpPWpGaD
Trametinib—Arthralgia—Methylprednisolone—ankylosing spondylitis	0.000647	0.00216	CcSEcCtD
Trametinib—Myalgia—Methylprednisolone—ankylosing spondylitis	0.000647	0.00216	CcSEcCtD
Trametinib—Eye disorder—Prednisone—ankylosing spondylitis	0.000646	0.00216	CcSEcCtD
Trametinib—Infestation NOS—Methotrexate—ankylosing spondylitis	0.000643	0.00215	CcSEcCtD
Trametinib—Infestation—Methotrexate—ankylosing spondylitis	0.000643	0.00215	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000642	0.00215	CcSEcCtD
Trametinib—MAP2K2—Immune System—ERAP1—ankylosing spondylitis	0.000635	0.00207	CbGpPWpGaD
Trametinib—Dry mouth—Triamcinolone—ankylosing spondylitis	0.000634	0.00212	CcSEcCtD
Trametinib—Renal failure—Methotrexate—ankylosing spondylitis	0.000633	0.00212	CcSEcCtD
Trametinib—Stomatitis—Methotrexate—ankylosing spondylitis	0.000627	0.0021	CcSEcCtD
Trametinib—Angiopathy—Prednisone—ankylosing spondylitis	0.000627	0.0021	CcSEcCtD
Trametinib—MAP2K1—Immune System—IL1R2—ankylosing spondylitis	0.000627	0.00204	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—HLA-C—ankylosing spondylitis	0.000626	0.00204	CbGpPWpGaD
Trametinib—Oedema—Triamcinolone—ankylosing spondylitis	0.000621	0.00208	CcSEcCtD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000618	0.00201	CbGpPWpGaD
Trametinib—Arrhythmia—Prednisone—ankylosing spondylitis	0.000617	0.00207	CcSEcCtD
Trametinib—Infection—Triamcinolone—ankylosing spondylitis	0.000617	0.00206	CcSEcCtD
Trametinib—Infection—Methylprednisolone—ankylosing spondylitis	0.000616	0.00206	CcSEcCtD
Trametinib—Haematuria—Methotrexate—ankylosing spondylitis	0.000614	0.00205	CcSEcCtD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000612	0.00199	CbGpPWpGaD
Trametinib—Insomnia—Prednisolone—ankylosing spondylitis	0.000611	0.00204	CcSEcCtD
Trametinib—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000608	0.00203	CcSEcCtD
Trametinib—Epistaxis—Methotrexate—ankylosing spondylitis	0.000607	0.00203	CcSEcCtD
Trametinib—Mental disorder—Prednisone—ankylosing spondylitis	0.000606	0.00203	CcSEcCtD
Trametinib—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000602	0.00201	CcSEcCtD
Trametinib—Erythema—Prednisone—ankylosing spondylitis	0.000602	0.00201	CcSEcCtD
Trametinib—Malnutrition—Prednisone—ankylosing spondylitis	0.000602	0.00201	CcSEcCtD
Trametinib—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.000601	0.00201	CcSEcCtD
Trametinib—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000599	0.002	CcSEcCtD
Trametinib—Hypertension—Dexamethasone—ankylosing spondylitis	0.000597	0.00199	CcSEcCtD
Trametinib—Hypertension—Betamethasone—ankylosing spondylitis	0.000597	0.00199	CcSEcCtD
Trametinib—MAP2K1—Immune System—ERAP1—ankylosing spondylitis	0.000594	0.00194	CbGpPWpGaD
Trametinib—MAP2K2—Toll-like Receptor Signaling Pathway—TNF—ankylosing spondylitis	0.000593	0.00193	CbGpPWpGaD
Trametinib—Myalgia—Betamethasone—ankylosing spondylitis	0.000588	0.00197	CcSEcCtD
Trametinib—Myalgia—Dexamethasone—ankylosing spondylitis	0.000588	0.00197	CcSEcCtD
Trametinib—MAP2K1—Innate Immune System—HLA-C—ankylosing spondylitis	0.000586	0.00191	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CARD9—ankylosing spondylitis	0.000581	0.00189	CbGpPWpGaD
Trametinib—Haemoglobin—Methotrexate—ankylosing spondylitis	0.000581	0.00194	CcSEcCtD
Trametinib—Haemorrhage—Methotrexate—ankylosing spondylitis	0.000578	0.00193	CcSEcCtD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000572	0.00187	CbGpPWpGaD
Trametinib—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.00057	0.00191	CcSEcCtD
Trametinib—Vision blurred—Prednisone—ankylosing spondylitis	0.000567	0.0019	CcSEcCtD
Trametinib—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000566	0.00189	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000566	0.00189	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000565	0.00189	CcSEcCtD
Trametinib—Oedema—Dexamethasone—ankylosing spondylitis	0.000564	0.00189	CcSEcCtD
Trametinib—Oedema—Betamethasone—ankylosing spondylitis	0.000564	0.00189	CcSEcCtD
Trametinib—Insomnia—Triamcinolone—ankylosing spondylitis	0.000562	0.00188	CcSEcCtD
Trametinib—Insomnia—Methylprednisolone—ankylosing spondylitis	0.000561	0.00188	CcSEcCtD
Trametinib—Infection—Dexamethasone—ankylosing spondylitis	0.00056	0.00187	CcSEcCtD
Trametinib—Infection—Betamethasone—ankylosing spondylitis	0.00056	0.00187	CcSEcCtD
Trametinib—Anaemia—Prednisone—ankylosing spondylitis	0.000556	0.00186	CcSEcCtD
Trametinib—MAP2K1—Toll-like Receptor Signaling Pathway—TNF—ankylosing spondylitis	0.000554	0.00181	CbGpPWpGaD
Trametinib—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000553	0.00185	CcSEcCtD
Trametinib—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000553	0.00185	CcSEcCtD
Trametinib—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000552	0.00185	CcSEcCtD
Trametinib—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000552	0.00185	CcSEcCtD
Trametinib—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.000545	0.00182	CcSEcCtD
Trametinib—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.000545	0.00182	CcSEcCtD
Trametinib—MAP2K1—Immune System—CARD9—ankylosing spondylitis	0.000543	0.00177	CbGpPWpGaD
Trametinib—Eye disorder—Methotrexate—ankylosing spondylitis	0.00054	0.00181	CcSEcCtD
Trametinib—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.000536	0.00179	CcSEcCtD
Trametinib—Fatigue—Triamcinolone—ankylosing spondylitis	0.000536	0.00179	CcSEcCtD
Trametinib—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000535	0.00179	CcSEcCtD
Trametinib—Angiopathy—Methotrexate—ankylosing spondylitis	0.000524	0.00175	CcSEcCtD
Trametinib—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000521	0.00174	CcSEcCtD
Trametinib—Hypertension—Prednisone—ankylosing spondylitis	0.000519	0.00174	CcSEcCtD
Trametinib—Chills—Methotrexate—ankylosing spondylitis	0.000518	0.00173	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.000514	0.00172	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.000514	0.00172	CcSEcCtD
Trametinib—Arthralgia—Prednisone—ankylosing spondylitis	0.000512	0.00171	CcSEcCtD
Trametinib—Myalgia—Prednisone—ankylosing spondylitis	0.000512	0.00171	CcSEcCtD
Trametinib—Insomnia—Dexamethasone—ankylosing spondylitis	0.00051	0.00171	CcSEcCtD
Trametinib—Insomnia—Betamethasone—ankylosing spondylitis	0.00051	0.00171	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000509	0.0017	CcSEcCtD
Trametinib—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000507	0.0017	CcSEcCtD
Trametinib—Mental disorder—Methotrexate—ankylosing spondylitis	0.000506	0.00169	CcSEcCtD
Trametinib—Erythema—Methotrexate—ankylosing spondylitis	0.000503	0.00168	CcSEcCtD
Trametinib—Malnutrition—Methotrexate—ankylosing spondylitis	0.000503	0.00168	CcSEcCtD
Trametinib—Dysgeusia—Methotrexate—ankylosing spondylitis	0.000492	0.00165	CcSEcCtD
Trametinib—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000491	0.00164	CcSEcCtD
Trametinib—Oedema—Prednisone—ankylosing spondylitis	0.000491	0.00164	CcSEcCtD
Trametinib—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.00049	0.00164	CcSEcCtD
Trametinib—Decreased appetite—Betamethasone—ankylosing spondylitis	0.00049	0.00164	CcSEcCtD
Trametinib—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.00049	0.00164	CcSEcCtD
Trametinib—Infection—Prednisone—ankylosing spondylitis	0.000488	0.00163	CcSEcCtD
Trametinib—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000487	0.00163	CcSEcCtD
Trametinib—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000487	0.00163	CcSEcCtD
Trametinib—Back pain—Methotrexate—ankylosing spondylitis	0.000486	0.00163	CcSEcCtD
Trametinib—Fatigue—Dexamethasone—ankylosing spondylitis	0.000486	0.00163	CcSEcCtD
Trametinib—Fatigue—Betamethasone—ankylosing spondylitis	0.000486	0.00163	CcSEcCtD
Trametinib—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000482	0.00161	CcSEcCtD
Trametinib—Skin disorder—Prednisone—ankylosing spondylitis	0.000477	0.0016	CcSEcCtD
Trametinib—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.000475	0.00159	CcSEcCtD
Trametinib—Vision blurred—Methotrexate—ankylosing spondylitis	0.000474	0.00158	CcSEcCtD
Trametinib—Anaemia—Methotrexate—ankylosing spondylitis	0.000465	0.00155	CcSEcCtD
Trametinib—MAP2K2—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	0.000463	0.00151	CbGpPWpGaD
Trametinib—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.000461	0.00154	CcSEcCtD
Trametinib—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.000461	0.00154	CcSEcCtD
Trametinib—MAP2K2—Disease—B3GNT2—ankylosing spondylitis	0.000456	0.00149	CbGpPWpGaD
Trametinib—Leukopenia—Methotrexate—ankylosing spondylitis	0.00045	0.00151	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.000447	0.0015	CcSEcCtD
Trametinib—Dizziness—Prednisolone—ankylosing spondylitis	0.000447	0.00149	CcSEcCtD
Trametinib—Asthenia—Triamcinolone—ankylosing spondylitis	0.000446	0.00149	CcSEcCtD
Trametinib—Abdominal pain—Betamethasone—ankylosing spondylitis	0.000446	0.00149	CcSEcCtD
Trametinib—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000446	0.00149	CcSEcCtD
Trametinib—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000446	0.00149	CcSEcCtD
Trametinib—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.000446	0.00149	CcSEcCtD
Trametinib—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000445	0.00149	CcSEcCtD
Trametinib—Insomnia—Prednisone—ankylosing spondylitis	0.000444	0.00149	CcSEcCtD
Trametinib—Pruritus—Triamcinolone—ankylosing spondylitis	0.00044	0.00147	CcSEcCtD
Trametinib—Cough—Methotrexate—ankylosing spondylitis	0.000439	0.00147	CcSEcCtD
Trametinib—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000439	0.00147	CcSEcCtD
Trametinib—MAP2K1—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	0.000433	0.00141	CbGpPWpGaD
Trametinib—Arthralgia—Methotrexate—ankylosing spondylitis	0.000428	0.00143	CcSEcCtD
Trametinib—Myalgia—Methotrexate—ankylosing spondylitis	0.000428	0.00143	CcSEcCtD
Trametinib—Decreased appetite—Prednisone—ankylosing spondylitis	0.000427	0.00143	CcSEcCtD
Trametinib—MAP2K1—Disease—B3GNT2—ankylosing spondylitis	0.000426	0.00139	CbGpPWpGaD
Trametinib—Rash—Prednisolone—ankylosing spondylitis	0.000426	0.00143	CcSEcCtD
Trametinib—Dermatitis—Prednisolone—ankylosing spondylitis	0.000426	0.00142	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000425	0.00142	CcSEcCtD
Trametinib—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000424	0.00142	CcSEcCtD
Trametinib—Fatigue—Prednisone—ankylosing spondylitis	0.000423	0.00142	CcSEcCtD
Trametinib—Headache—Prednisolone—ankylosing spondylitis	0.000423	0.00142	CcSEcCtD
Trametinib—Constipation—Prednisone—ankylosing spondylitis	0.00042	0.0014	CcSEcCtD
Trametinib—Dizziness—Triamcinolone—ankylosing spondylitis	0.000411	0.00137	CcSEcCtD
Trametinib—Dizziness—Methylprednisolone—ankylosing spondylitis	0.00041	0.00137	CcSEcCtD
Trametinib—Infection—Methotrexate—ankylosing spondylitis	0.000408	0.00136	CcSEcCtD
Trametinib—Asthenia—Dexamethasone—ankylosing spondylitis	0.000405	0.00135	CcSEcCtD
Trametinib—Asthenia—Betamethasone—ankylosing spondylitis	0.000405	0.00135	CcSEcCtD
Trametinib—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000402	0.00135	CcSEcCtD
Trametinib—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.000402	0.00134	CcSEcCtD
Trametinib—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000402	0.00134	CcSEcCtD
Trametinib—Nausea—Prednisolone—ankylosing spondylitis	0.000401	0.00134	CcSEcCtD
Trametinib—Pruritus—Dexamethasone—ankylosing spondylitis	0.000399	0.00133	CcSEcCtD
Trametinib—Pruritus—Betamethasone—ankylosing spondylitis	0.000399	0.00133	CcSEcCtD
Trametinib—Skin disorder—Methotrexate—ankylosing spondylitis	0.000399	0.00133	CcSEcCtD
Trametinib—MAP2K2—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000397	0.0013	CbGpPWpGaD
Trametinib—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.000397	0.00133	CcSEcCtD
Trametinib—Vomiting—Triamcinolone—ankylosing spondylitis	0.000395	0.00132	CcSEcCtD
Trametinib—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000394	0.00132	CcSEcCtD
Trametinib—Rash—Triamcinolone—ankylosing spondylitis	0.000392	0.00131	CcSEcCtD
Trametinib—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000391	0.00131	CcSEcCtD
Trametinib—Rash—Methylprednisolone—ankylosing spondylitis	0.000391	0.00131	CcSEcCtD
Trametinib—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000391	0.00131	CcSEcCtD
Trametinib—Headache—Triamcinolone—ankylosing spondylitis	0.000389	0.0013	CcSEcCtD
Trametinib—Headache—Methylprednisolone—ankylosing spondylitis	0.000388	0.0013	CcSEcCtD
Trametinib—Abdominal pain—Prednisone—ankylosing spondylitis	0.000388	0.0013	CcSEcCtD
Trametinib—Body temperature increased—Prednisone—ankylosing spondylitis	0.000388	0.0013	CcSEcCtD
Trametinib—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000386	0.00129	CcSEcCtD
Trametinib—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000386	0.00129	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.000374	0.00125	CcSEcCtD
Trametinib—Dizziness—Betamethasone—ankylosing spondylitis	0.000373	0.00125	CcSEcCtD
Trametinib—Dizziness—Dexamethasone—ankylosing spondylitis	0.000373	0.00125	CcSEcCtD
Trametinib—MAP2K1—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000372	0.00121	CbGpPWpGaD
Trametinib—Insomnia—Methotrexate—ankylosing spondylitis	0.000371	0.00124	CcSEcCtD
Trametinib—MAP2K2—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000371	0.00121	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—HLA-B—ankylosing spondylitis	0.00037	0.00121	CbGpPWpGaD
Trametinib—Nausea—Triamcinolone—ankylosing spondylitis	0.000369	0.00123	CcSEcCtD
Trametinib—Nausea—Methylprednisolone—ankylosing spondylitis	0.000368	0.00123	CcSEcCtD
Trametinib—MAP2K2—Immune System—HLA-C—ankylosing spondylitis	0.000365	0.00119	CbGpPWpGaD
Trametinib—Vomiting—Betamethasone—ankylosing spondylitis	0.000359	0.0012	CcSEcCtD
Trametinib—Vomiting—Dexamethasone—ankylosing spondylitis	0.000359	0.0012	CcSEcCtD
Trametinib—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000357	0.00119	CcSEcCtD
Trametinib—Rash—Betamethasone—ankylosing spondylitis	0.000356	0.00119	CcSEcCtD
Trametinib—Rash—Dexamethasone—ankylosing spondylitis	0.000356	0.00119	CcSEcCtD
Trametinib—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000355	0.00119	CcSEcCtD
Trametinib—Dermatitis—Betamethasone—ankylosing spondylitis	0.000355	0.00119	CcSEcCtD
Trametinib—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000354	0.00118	CcSEcCtD
Trametinib—Fatigue—Methotrexate—ankylosing spondylitis	0.000354	0.00118	CcSEcCtD
Trametinib—Headache—Dexamethasone—ankylosing spondylitis	0.000353	0.00118	CcSEcCtD
Trametinib—Headache—Betamethasone—ankylosing spondylitis	0.000353	0.00118	CcSEcCtD
Trametinib—Asthenia—Prednisone—ankylosing spondylitis	0.000352	0.00118	CcSEcCtD
Trametinib—Pruritus—Prednisone—ankylosing spondylitis	0.000347	0.00116	CcSEcCtD
Trametinib—MAP2K1—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000347	0.00113	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—HLA-B—ankylosing spondylitis	0.000346	0.00113	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HLA-C—ankylosing spondylitis	0.000341	0.00111	CbGpPWpGaD
Trametinib—Diarrhoea—Prednisone—ankylosing spondylitis	0.000336	0.00112	CcSEcCtD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000336	0.00109	CbGpPWpGaD
Trametinib—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000336	0.00112	CcSEcCtD
Trametinib—Nausea—Betamethasone—ankylosing spondylitis	0.000335	0.00112	CcSEcCtD
Trametinib—Nausea—Dexamethasone—ankylosing spondylitis	0.000335	0.00112	CcSEcCtD
Trametinib—MAP2K2—Innate Immune System—CRP—ankylosing spondylitis	0.000327	0.00107	CbGpPWpGaD
Trametinib—Dizziness—Prednisone—ankylosing spondylitis	0.000325	0.00109	CcSEcCtD
Trametinib—Abdominal pain—Methotrexate—ankylosing spondylitis	0.000324	0.00109	CcSEcCtD
Trametinib—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000324	0.00109	CcSEcCtD
Trametinib—MAP2K2—Immune System—IL1RN—ankylosing spondylitis	0.000317	0.00103	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—TLR4—ankylosing spondylitis	0.000314	0.00102	CbGpPWpGaD
Trametinib—Vomiting—Prednisone—ankylosing spondylitis	0.000312	0.00104	CcSEcCtD
Trametinib—Rash—Prednisone—ankylosing spondylitis	0.00031	0.00104	CcSEcCtD
Trametinib—Dermatitis—Prednisone—ankylosing spondylitis	0.000309	0.00103	CcSEcCtD
Trametinib—Headache—Prednisone—ankylosing spondylitis	0.000308	0.00103	CcSEcCtD
Trametinib—MAP2K1—Innate Immune System—CRP—ankylosing spondylitis	0.000306	0.000998	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL1RN—ankylosing spondylitis	0.000296	0.000966	CbGpPWpGaD
Trametinib—Asthenia—Methotrexate—ankylosing spondylitis	0.000294	0.000985	CcSEcCtD
Trametinib—MAP2K1—Innate Immune System—TLR4—ankylosing spondylitis	0.000294	0.000957	CbGpPWpGaD
Trametinib—Nausea—Prednisone—ankylosing spondylitis	0.000292	0.000976	CcSEcCtD
Trametinib—Pruritus—Methotrexate—ankylosing spondylitis	0.00029	0.000971	CcSEcCtD
Trametinib—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000281	0.000939	CcSEcCtD
Trametinib—MAP2K2—Immune System—CD79A—ankylosing spondylitis	0.000278	0.000907	CbGpPWpGaD
Trametinib—Dizziness—Methotrexate—ankylosing spondylitis	0.000271	0.000908	CcSEcCtD
Trametinib—MAP2K2—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000264	0.000861	CbGpPWpGaD
Trametinib—Vomiting—Methotrexate—ankylosing spondylitis	0.000261	0.000873	CcSEcCtD
Trametinib—MAP2K1—Immune System—CD79A—ankylosing spondylitis	0.00026	0.000848	CbGpPWpGaD
Trametinib—Rash—Methotrexate—ankylosing spondylitis	0.000259	0.000865	CcSEcCtD
Trametinib—Dermatitis—Methotrexate—ankylosing spondylitis	0.000259	0.000865	CcSEcCtD
Trametinib—Headache—Methotrexate—ankylosing spondylitis	0.000257	0.00086	CcSEcCtD
Trametinib—MAP2K1—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000247	0.000805	CbGpPWpGaD
Trametinib—Nausea—Methotrexate—ankylosing spondylitis	0.000244	0.000815	CcSEcCtD
Trametinib—MAP2K2—Immune System—IL1A—ankylosing spondylitis	0.000228	0.000744	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD40LG—ankylosing spondylitis	0.000227	0.000739	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000219	0.000714	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HLA-B—ankylosing spondylitis	0.000216	0.000703	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL1A—ankylosing spondylitis	0.000213	0.000696	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD40LG—ankylosing spondylitis	0.000212	0.000692	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000205	0.000668	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HLA-B—ankylosing spondylitis	0.000202	0.000658	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HLA-A—ankylosing spondylitis	0.0002	0.000652	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CRP—ankylosing spondylitis	0.000191	0.000622	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HLA-A—ankylosing spondylitis	0.000187	0.00061	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HLA-A—ankylosing spondylitis	0.000184	0.000602	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—TLR4—ankylosing spondylitis	0.000183	0.000596	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—B3GNT2—ankylosing spondylitis	0.00018	0.000586	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CRP—ankylosing spondylitis	0.000178	0.000582	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HLA-A—ankylosing spondylitis	0.000173	0.000563	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—TLR4—ankylosing spondylitis	0.000171	0.000558	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—TNF—ankylosing spondylitis	0.000168	0.000547	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TNF—ankylosing spondylitis	0.000157	0.000512	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MMP3—ankylosing spondylitis	0.000156	0.000508	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MMP3—ankylosing spondylitis	0.000146	0.000476	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	9.65e-05	0.000315	CbGpPWpGaD
